Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Tango Therapeutics (TNGX) EBT: 2020-2024

Historic EBT for Tango Therapeutics (TNGX) over the last 5 years, with Dec 2024 value amounting to -$130.1 million.

  • Tango Therapeutics' EBT rose 154.53% to $15.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$100.4 million, marking a year-over-year increase of 18.49%. This contributed to the annual value of -$130.1 million for FY2024, which is 28.03% down from last year.
  • Per Tango Therapeutics' latest filing, its EBT stood at -$130.1 million for FY2024, which was down 28.03% from -$101.6 million recorded in FY2023.
  • Over the past 5 years, Tango Therapeutics' EBT peaked at -$52.0 million during FY2020, and registered a low of -$130.1 million during FY2024.
  • Moreover, its 3-year median value for EBT was -$108.1 million (2022), whereas its average is -$113.3 million.
  • In the last 5 years, Tango Therapeutics' EBT slumped by 86.60% in 2022 and then rose by 6.02% in 2023.
  • Yearly analysis of 5 years shows Tango Therapeutics' EBT stood at -$52.0 million in 2020, then fell by 11.49% to -$57.9 million in 2021, then crashed by 86.60% to -$108.1 million in 2022, then climbed by 6.02% to -$101.6 million in 2023, then declined by 28.03% to -$130.1 million in 2024.